The fastest growing
Neurotoxin in the last 4 years

It’s pronounced

An intentionally designed, high quality product
that drives patient satisfaction.*

*81% of patients are satisfied with receiving Jeuveau treatments.

This page is meant for Healthcare Professionals

If you are a potential patient, please learn more about the product here.

Jeuveau’s
Bold Clinical Evolution

5 Clinical Studies. 8 Peer Reviewed Articles. 1 New First-Of-Its-Kind Study.

2019

Pivotal Trials

Demonstrated safety and efficacy vs placebo (EV-001 & EV-002, n=654).1
‍Primary endpoint: 68% (n=246) and 70% (n=246) of Jeuveau patients with moderate to severe frown lines had ≥ 2-grade composite (investigator and subject assessments) GLS improvement at maximum frown at Day 30, compared to 1% (n= 84; n=78) for placebo.1

2019

FDA Approval

Jeuveau launches as the first aesthetics-only neurotoxin.2

2020

Face off against BOTOX® Cosmetic

Proven results in the largest head-to-head study of its kind (EVB-003, n=540).  Demonstrated non-inferiority and numerically favored in 26 out of 30 exploratory endpoints.3*

2021

Post-hoc analysis: Skin of color

Demonstrated safety and efficacy in patients with skin of color. (EV-001 & EV-002)4

2021

Long-term safety studies5,6

EV-004 and EV-006

2022

Post-hoc analysis: MIllennials

100% of millennials achieved a ≥1-point improvement on the GLS at maximum frown by investigator assessment at Days 7, 14, and 30. (EV-001, EV-002 & EVB-003; n=65)7

2022

Post-hoc analysis: Men

More men treated with Jeuveau (n=25) achieved a GLS score improvement at every visit by investigator assessment (vs. BOTOX® Cosmetic; n=31) (absolute overall mean difference of 10.1%, but not statistically significant). (EVB-003)8

2024

2M+ treatments in the U.S.

2025

JAMA Study

Head-to-head comparison of four toxins using 3D photogrammetry9

*Based on a non-inferiority study that was conducted to show the effect of a treatment was not worse than the original treatment.

Jeuveau In Direct Comparison

4 Neurotoxins.
1 Study.
The Results are In.9

Objective 3D photogrammetry plus FACE-Q patient-reported outcomes present an advanced measure of performance.

Fast onset

of action

Jeuveau and Dysport® displayed the most rapid onset at Day 3 compared to BOTOX Cosmetic and Xeomin®.

Strong peak effect

Jeuveau achieved the highest peak effect at Day 30, highlighting its performance profile.

Long duration

of effect

At day 180, Jeuveau demonstrated a numerically greater effect than Dysport and Xeomin, and a significantly greater effect compared to BOTOX Cosmetic.

Percentage of maximum effect at each visit (n=139)1

Visit Day

Study Design: Single-center, double-blind, randomized clinical trial to assess the effect of 4 botulinum toxin A formulations on glabellar strain using dynamic 3-dimensional photogrammetry. 142 females aged 30 to 65 years were randomized 1:1:1:1 into 4 treatment arms: 1 dose of 20 units of onabotulinumtoxinA (BOTOX Cosmetic) (n=35); 1 dose of 50 units of abobotulinumtoxinA (Dysport) (n=36); 1 dose of 20 units of prabotulinumtoxinA (Jeuveau) (n=36); or 1 dose of 20 units of incobotulinumtoxinA (Xeomin) (n=36) into the glabellar region (GR). Follow up occurred at Days 3, 30, 90, and 180. The primary outcome was change in GR dynamic strain after injection over time. The percentage of maximum treatment effect (MTE) at each visit was examined to delineate onset and duration.

Jeuveau demonstrated fast onset, numerically greatest effect at Day 30 and Day 90, and numerically greatest longevity at Day 180 among BOTOX Cosmetic, Dysport, and Xeomin.

Across all treatment arms and timepoints, there were no statistically significant differences (p>0.05), except: At Day 3, Dysport MTE was significantly higher than BOTOX Cosmetic (p=0.001) and Xeomin (p=0.002); and at Day 180, Jeuveau MTE was statistically significantly higher than BOTOX Cosmetic (p=0.03).

Learn more

9. Lemdani, et al., Comparison of Botulinum Toxin A Formulations For Glabellar Strain Treatment In Woman. JAMA Dermatol. 2025.

In Another Phase III Study

FACE OFF AGAINST

BOTOX® COSMETIC3

At Day 30
BOTOX Cosmetic
82.8%
of people studied
saw improvement
(n=244)
Two Jeuveau vials
At Day 30
Jeuveau
87.2%
of people studied
saw improvement
(n=235)

We’re so confident in our results,
Jeuveau was put to the test against legacy neurotoxin BOTOX Cosmetic.

Evolus conducted the largest head-to-head aesthetic phase III study and found that Jeuveau demonstrated non-inferiority to BOTOX Cosmetic in the treatment of moderate to severe glabellar lines in adults based on a GLS score of 0 or 1 at maximum frown on Day 30 by investigator assessment.** 

**A non-inferiority study is conducted to show that the effect of a treatment is not worse than the original treatment. 

Primary Endpoint

GLS score of 0 or 1 at maximum frown on Day 30 by investigator assessment.

Non-inferiority margin5*: 10%

In that same study,

Jeuveau was numerically favored
in 26/30 exploratory endpoints.3†

†️Investigator and subject assessment of GLS ≥1-point improvement at maximum frown at days 2, 14, 30, 90, 120, and 150.

Learn more

³ Rzany BJ, Ascher B, Avelar RL, et al. A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase 3, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients. Aesthet Surg J. 2020.

Intentional Design

Jeuveau is a 900 kDa neurotoxin designed with purpose in California. Our unique manufacturing combines vacuum-dried processing with proprietary

Hi-Pure™ technology

resulting in ≥95% product purity and a
diffusion profile that supports results as you intend them.10,11

Machines on the Jeuveau production line.

Unique manufacturing

900 KDA MOLECULE

Jeuveau utilizes the entire 900kDa complex. Accessory proteins are active and may contribute to the efficacy.9

HI-PURE TECHNOLOGY

Our HI-PURE™ Technology allow for the purification of the toxin with at least

95% purity.12

VACUUM-Drying

Avoids crystal formation and minimizes product impurities, maintaining the integrity of the toxin.9

THE POWER OF PRECISION IS IN YOUR HANDS

Mechanism of Action

When used in conjunction with intramuscular injection for moderate to severe glabellar lines,1,12 Jeuveau offers:

  • A precise, tight field of effect that puts control in your hands12
  • Natural-looking results, exactly where you want them1,11
  • Consistent outcomes, for consistently satisfied patients1,11*

*87% of injectors consider Jeuveau to be a precise product when injected intramuscularly.8

Ready to try Jeuveau at your practice?

Create a Myevolus account

PATIENT SATISFACTION 

FAST ACTING LONG LASTING RESULTS 

91% of Jeuveau patients report being satisfied with their results, enjoying smoother frown lines in as little as two days* that last for up to four months.5†

*About 50% of people begin showing improvement after two days (≥1-grade improvement by physician assessment). Most people (~69%) achieve complete results by day 30 (≥2-grade improvement by physician and patient assessments).
†On average, Jeuveau patients receive 3 treatments a year.

Consumer Pulse Survey 2024, Data on file. (N=424). 91% of Jeuveau patients treated within the prior 3 months and with at least 5 previous treatments rated themselves as satisfied or extremely satisfied with their treatments.

Day 0 & Day 30
Day 2
Day 30
Day 120
Day 0 & Day 30
Day 2
Day 30
Day 120
Soo Youn
Soo Youn
Soo Youn
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Soo Youn
Soo Youn
Soo Youn
Soo Youn
Soo Youn
Soo Youn
Soo Youn
David
David
David
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
David
David
David
David
David
David
David
Arielle
Arielle
Arielle
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Arielle
Arielle
Arielle
Arielle
Arielle
Arielle
Arielle
Sarah
Sarah
Sarah
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Sarah
Sarah
Sarah
Sarah
Sarah
Sarah
Sarah
Tajah
Tajah
Tajah
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tajah
Tajah
Tajah
Tajah
Tajah
Tajah
Tajah
Lisa
Lisa
Lisa
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Lisa
Lisa
Lisa
Lisa
Lisa
Lisa
Lisa
Tia
Tia
Tia
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tia
Tia
Tia
Tia
Tia
Tia
Tia
Shai
Shai
Shai
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Shai
Shai
Shai
Shai
Shai
Shai
Shai
Tugba
Tugba
Tugba
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tugba
Tugba
Tugba
Tugba
Tugba
Tugba
Tugba
Josephine
Josephine
Josephine
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Josephine
Josephine
Josephine
Josephine
Josephine
Josephine
Josephine
Soo Youn
David
Arielle
Sarah
Tajah
Lisa
Tia
Shai
Tugba
Josephine
See More Results
Right arrow
At maximum frown. Actual patient. Results may vary.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

Soo Youn
Soo Youn
David
David
Arielle
Arielle
Sarah
Sarah
Tajah
Tajah
Lisa
Lisa
Tia
Tia
Shai
Shai
Tugba
Tugba
Josephine
Josephine
See More Results
Right arrow
At maximum frown. Jeuveau® patient. Individual results may vary.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3

In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.

In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3

In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.

Ready to join the Evolus Experience?

Start setting up your MyEvolus account and see all that Evolus can offer you today.

Create a Myevolus account

References

  1. Jeuveau® [package insert]. Evolus, Inc; 2023.
  2. Kim CS, Song KY, Min KM, An YD, inventors; Daewoong Co, Ltd, assignee. Method for production of botulinum toxin. US patent 9,512,418 B2. December 6, 2016.
  3. Kaminer MS, Cox SE, Fagien S, Kaufman J, Lupo M, Shamban A. Re-examining the optimal use of neuromodulators and the changing landscape: A consensus panel update. J Drugs Dermatol. 2020;19(4 suppl 1):s5-15.
  4. Beer KR, Shamban AT, Avelar RL, Gross JE, Jonker A. Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase 3 studies. Dermatol Surg. 2019;45(11):1381-1393.
  5. Rzany BJ, Ascher B, Avelar RL, et al. A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase 3, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients. Aesthet Surg J. 2020;40(4):413-429.
  6. Kaufman-Janette J, Avelar RL, Biesman BS, et al. The first of two one-year, multicenter, open-label, repeat-dose, phase II safety studies of prabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients[published correction appears in Aesthet Sur J. 2021 Nov 12;41(12):1494. doi: 10.1093/asj/sjab229]. Aesthet Surg J. 2021;41(12):1409-1422.
  7. Lorenc ZP, Adelglass JM, Avelar RL, et al. The second of two one-year, multicenter, open-label, repeat-dose, phase II safety studies of prabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients [published correction appears in Aesthet Surg J. 2021 Nov 12;41(12):1494-1495. doi: 10.1093/asj/sjab230]. Aesthet Surg J. 2021;41(12):1423-1438.
  8. Avelar, Rui MD. Botulinum Toxin Accessory Proteins: Are They Just an Accessory?. Dermatologic Surgery 50(9S):p S38-S41, September 2024.
  9. Data on file; REF-00258. Evolus, Inc., Newport Beach, CA.

Results That Speak Volumes

Jeuveau demonstrated a proven safety profile in 5 clinical studies, all part of the Transparency Clinical Program:

  • 2 phase III pivotal studies (n=645)4
  • The largest head-to-head aesthetic EU/Canada phase III trial vs BOTOX® Cosmetic (n=540)5,* 
  • 2 long-term safety studies (n=922)6,7

In the 2 U.S. pivotal phase III studies, 68% and 70% of Jeuveau patients with moderate to severe frown lines had a 2-grade or better physician- and patient-rated improvement (none or mild frown lines) at Day 30, compared to 1% for placebo.

* Jeuveau demonstrated non-inferiority to BOTOX® Cosmetic in the treatment of moderate to severe glabellar lines in adults based on a GLS score of 0 or 1 at maximum front on Day 30 by investigator assessment.

Discover

Jeuveau®
(prabotulinumtoxinA-xvfs)
Evolysse™Evolus Rewards™Club Evolus™Beauty BlogClinical Studies

Company

CareersEvolus Investor RelationsContact Us
Terms & ConditionsPrivacy Policy

Exclusively licensed and manufactured for: Evolus, Inc., 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660

©2025 Evolus, Inc. All rights reserved. All trademarks are the property of their respective owners.

*Your Club Evolus membership covers 20 units of Jeuveau per treatment, with a minimum of 90 days between each treatment. Units do not accrue if you wait more than 90 days between treatments. You will pay your provider directly for any additional treatments you receive. Cannot be combined with any other offer. Club Evolus members will be automatically opted out of Evolus Rewards™ upon enrollment. You can manage your Club Evolus account and payment method through your club.evolus.com login. If you cancel within the first three months a $100 cancellation fee will apply. Your Club Evolus membership is non-transferable and payments are non-refundable.

IMPORTANT SAFETY INFORMATION FOR JEUVEAU® (prabotulinumtoxinA-xvfs)

Expand
Add icon

WARNING: DISTANT SPREAD OF TOXIN EFFECT: The effects of all botulinum toxin products,including JEUVEAU, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection.Swallowing and breathing difficulties can be life threatening and there have been reports of death. JEUVEAU is not approved for the treatment of spasticity or any conditions other than glabellarlines.

CONTRAINDICATIONS

JEUVEAU is contraindicated in individuals with known hypersensitivity to any botulinum toxinpreparation or to any of the components in the formulation, and in the presence of infection at the
proposed injection site(s).